You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NamePaliperidone palmitateProduct NameINVEGA SUSTENNA®Therapeutic AreaNervous SystemProduct ClassPsycholepticsPharmacological SubgroupAntipsychoticsChemical SubgroupOther AntipsychoticsCondition StudiedSchizophrenia
Sponsor Protocol NumberR092670SCH3010Enrollment1044Data PartnerJohnson & Johnson% Female36.9%Mean/Median Age (Years)38.4% WhiteN/A
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2024-0060 : Using Synthetic Controls to Improve Randomised Controlled Trials for Rare Diseases
- 2023-5195 : Predictive modeling of adverse events and symptoms patterns in large scale clinical trials
- 2022-4992 : Temporal trajectories of side-effects associated with antipsychotic treatment ? An individual participant data meta-analysis
- 2021-4754 : Harnessing clinical trial data to inform real-world clinical decision making in the treatment of schizophrenia
- 2021-4705 : Inflammation and the Metabolic Syndrome in Psychosis
- 2021-4667 : Estimation of Geographic and Demographic Variabilities Associated with Schizophrenia Age of Onset and Duration of Untreated Psychosis
- 2019-3958 : Machine Learning for predicting treatment efficacy and clinical categorizations across mental health disorders.
- 2019-3827 : Prediction of outcome and adverse events in antipsychotic treatment
- 2017-1966 : Psychosis break through antipsychotic maintenance medication: An individual participant data meta-analysis